中国傈僳族人群中重要药物基因变异的遗传多态性。

IF 1.7 4区 医学 Q3 PHARMACOLOGY & PHARMACY
Hongyan Lu, Zhanhao Zhang, Yuliang Wang, Li Wang, Dongya Yuan, Yongjun He, Tianbo Jin
{"title":"中国傈僳族人群中重要药物基因变异的遗传多态性。","authors":"Hongyan Lu,&nbsp;Zhanhao Zhang,&nbsp;Yuliang Wang,&nbsp;Li Wang,&nbsp;Dongya Yuan,&nbsp;Yongjun He,&nbsp;Tianbo Jin","doi":"10.2217/pme-2022-0117","DOIUrl":null,"url":null,"abstract":"<p><p><b>Aim:</b> Interindividual and interethnic differences in drug efficacy drive the development and progress of pharmacogenomics and precision medicine. This study was performed to enrich the pharmacogenomic information for the Lisu population from China. <b>Methods:</b> 54 very important pharmacogene variants were selected from PharmGKB and genotyped in 199 Lisu individuals. The genotype distribution data of 26 populations were downloaded from the 1000 Genomes Project and analyzed with the χ<sup>2</sup> test. <b>Results:</b> Among the 26 populations in the 1000 Genomes Project, African Caribbeans in Barbados; Esan in Nigeria; Gambian in Western Divisions, The Gambia; Luhya in Webuye, Kenya; Yoruba in Ibadan; Finnish in Finland; Toscani in Italy and Sri Lankan Tamil in the UK were the top eight nationalities with the most significant differences in genotype distribution from the Lisu population. The loci of <i>CYP3A</i>5 rs776746, <i>KCNH2</i> rs1805123, <i>ACE</i> rs4291, <i>SLC19A1</i> rs1051298 and <i>CYP2D6</i> rs1065852 were significantly different in the Lisu. <b>Conclusion:</b> The results showed that there were substantial differences in SNPs of very important pharmacogene variants, which can provide a theoretical basis for individualized drug use for the Lisu.</p>","PeriodicalId":19753,"journal":{"name":"Personalized medicine","volume":"20 3","pages":"239-249"},"PeriodicalIF":1.7000,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Genetic polymorphisms of very important pharmacogene variants in the Chinese Lisu population.\",\"authors\":\"Hongyan Lu,&nbsp;Zhanhao Zhang,&nbsp;Yuliang Wang,&nbsp;Li Wang,&nbsp;Dongya Yuan,&nbsp;Yongjun He,&nbsp;Tianbo Jin\",\"doi\":\"10.2217/pme-2022-0117\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b>Aim:</b> Interindividual and interethnic differences in drug efficacy drive the development and progress of pharmacogenomics and precision medicine. This study was performed to enrich the pharmacogenomic information for the Lisu population from China. <b>Methods:</b> 54 very important pharmacogene variants were selected from PharmGKB and genotyped in 199 Lisu individuals. The genotype distribution data of 26 populations were downloaded from the 1000 Genomes Project and analyzed with the χ<sup>2</sup> test. <b>Results:</b> Among the 26 populations in the 1000 Genomes Project, African Caribbeans in Barbados; Esan in Nigeria; Gambian in Western Divisions, The Gambia; Luhya in Webuye, Kenya; Yoruba in Ibadan; Finnish in Finland; Toscani in Italy and Sri Lankan Tamil in the UK were the top eight nationalities with the most significant differences in genotype distribution from the Lisu population. The loci of <i>CYP3A</i>5 rs776746, <i>KCNH2</i> rs1805123, <i>ACE</i> rs4291, <i>SLC19A1</i> rs1051298 and <i>CYP2D6</i> rs1065852 were significantly different in the Lisu. <b>Conclusion:</b> The results showed that there were substantial differences in SNPs of very important pharmacogene variants, which can provide a theoretical basis for individualized drug use for the Lisu.</p>\",\"PeriodicalId\":19753,\"journal\":{\"name\":\"Personalized medicine\",\"volume\":\"20 3\",\"pages\":\"239-249\"},\"PeriodicalIF\":1.7000,\"publicationDate\":\"2023-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Personalized medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2217/pme-2022-0117\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Personalized medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2217/pme-2022-0117","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

摘要

目的:药物疗效的个体间和种族间差异推动了药物基因组学和精准医学的发展和进步。本研究旨在丰富中国傈僳族人群的药物基因组学信息。方法:从199例傈僳族人的PharmGKB中筛选出54个重要的药物基因变异进行基因分型。从千人基因组计划中下载26个种群的基因型分布数据,采用χ2检验进行分析。结果:在“千人基因组计划”的26个种群中,巴巴多斯的非洲加勒比人;尼日利亚的Esan;冈比亚西部地区的冈比亚人;肯尼亚Webuye的Luhya;伊巴丹的约鲁巴人;芬兰语;意大利的托斯卡尼人和英国的斯里兰卡泰米尔人是与傈僳族人群基因型分布差异最大的前8个民族。CYP3A5位点rs776746、KCNH2位点rs1805123、ACE位点rs4291、SLC19A1位点rs1051298、CYP2D6位点rs1065852在傈僳族中存在显著差异。结论:结果显示,傈僳族非常重要的药基因变异的snp存在较大差异,可为傈僳族个体化用药提供理论依据。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Genetic polymorphisms of very important pharmacogene variants in the Chinese Lisu population.

Aim: Interindividual and interethnic differences in drug efficacy drive the development and progress of pharmacogenomics and precision medicine. This study was performed to enrich the pharmacogenomic information for the Lisu population from China. Methods: 54 very important pharmacogene variants were selected from PharmGKB and genotyped in 199 Lisu individuals. The genotype distribution data of 26 populations were downloaded from the 1000 Genomes Project and analyzed with the χ2 test. Results: Among the 26 populations in the 1000 Genomes Project, African Caribbeans in Barbados; Esan in Nigeria; Gambian in Western Divisions, The Gambia; Luhya in Webuye, Kenya; Yoruba in Ibadan; Finnish in Finland; Toscani in Italy and Sri Lankan Tamil in the UK were the top eight nationalities with the most significant differences in genotype distribution from the Lisu population. The loci of CYP3A5 rs776746, KCNH2 rs1805123, ACE rs4291, SLC19A1 rs1051298 and CYP2D6 rs1065852 were significantly different in the Lisu. Conclusion: The results showed that there were substantial differences in SNPs of very important pharmacogene variants, which can provide a theoretical basis for individualized drug use for the Lisu.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Personalized medicine
Personalized medicine 医学-药学
CiteScore
3.30
自引率
4.30%
发文量
49
审稿时长
6-12 weeks
期刊介绍: Personalized Medicine (ISSN 1741-0541) translates recent genomic, genetic and proteomic advances into the clinical context. The journal provides an integrated forum for all players involved - academic and clinical researchers, pharmaceutical companies, regulatory authorities, healthcare management organizations, patient organizations and others in the healthcare community. Personalized Medicine assists these parties to shape thefuture of medicine by providing a platform for expert commentary and analysis. The journal addresses scientific, commercial and policy issues in the field of precision medicine and includes news and views, current awareness regarding new biomarkers, concise commentary and analysis, reports from the conference circuit and full review articles.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信